{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:12:42Z","timestamp":1786979562876,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02265-y","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:43:17Z","timestamp":1779766997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting mTOR with vistusertib attenuates metabolic steatohepatitis and prevents HCC development"],"prefix":"10.1007","volume":"75","author":[{"given":"Nidhi","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Panneerselvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-737X","authenticated-orcid":false,"given":"Sai Balaji","family":"Andugulapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2265_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cld.2023.01.019","volume":"27","author":"SA Alqahtani","year":"2023","unstructured":"Alqahtani SA, Chan W-K, Yu M-L. Hepatic outcomes of nonalcoholic fatty liver disease including cirrhosis and hepatocellular carcinoma. Clin Liver Dis. 2023;27:211\u201323. https:\/\/doi.org\/10.1016\/j.cld.2023.01.019.","journal-title":"Clin Liver Dis"},{"key":"2265_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3350\/cmh.2023.0359","volume":"29","author":"M-L Yeh","year":"2023","unstructured":"Yeh M-L, Yu M-L. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: updates of nomenclature and impact on clinical trials. Clin Mol Hepatol. 2023;29:969\u201372. https:\/\/doi.org\/10.3350\/cmh.2023.0359.","journal-title":"Clin Mol Hepatol"},{"key":"2265_CR3","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/apt.17981","volume":"59","author":"N Noureddin","year":"2024","unstructured":"Noureddin N, Huang DQ, Bettencourt R, Siddiqi H, Majzoub AM, Nayfeh T, et al. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59:1521\u20136. https:\/\/doi.org\/10.1111\/apt.17981.","journal-title":"Aliment Pharmacol Ther"},{"key":"2265_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156080","author":"A Armandi","year":"2025","unstructured":"Armandi A, Rosso C, Caviglia GP, Bugianesi E. An updated overview on hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: trends, pathophysiology and risk-based surveillance. Metabolism. 2025. https:\/\/doi.org\/10.1016\/j.metabol.2024.156080.","journal-title":"Metabolism"},{"key":"2265_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1410668","author":"Y Ma","year":"2024","unstructured":"Ma Y, Wang J, Xiao W, Fan X. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1410668.","journal-title":"Front Med"},{"key":"2265_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604837","author":"S Shi","year":"2025","unstructured":"Shi S, Zhou Y, Zhang H, Zhang J. TREM2 in MASH: integrating lipid metabolism and immune response. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1604837.","journal-title":"Front Immunol"},{"key":"2265_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411\u201328. https:\/\/doi.org\/10.1038\/s41575-019-0145-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2265_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73150-z","volume":"14","author":"A Schmidt-Christensen","year":"2024","unstructured":"Schmidt-Christensen A, Eriksson G, Laprade WM, Pirzamanbein B, H\u00f6rnberg M, Linde K, et al. Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH. Sci Rep. 2024;14:23014. https:\/\/doi.org\/10.1038\/s41598-024-73150-z.","journal-title":"Sci Rep"},{"key":"2265_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041266","author":"G Ferr\u00edn","year":"2020","unstructured":"Ferr\u00edn G, Guerrero M, Amado V, Rodr\u00edguez-Per\u00e1lvarez M, la Mata M. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21041266.","journal-title":"Int J Mol Sci"},{"key":"2265_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.817916","author":"R Huang","year":"2022","unstructured":"Huang R, Dai Q, Yang R, Duan Y, Zhao Q, Haybaeck J, et al. A review: PI3K\/AKT\/mTOR signaling pathway and its regulated eukaryotic translation initiation factors may be a potential therapeutic target in esophageal squamous cell carcinoma. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.817916.","journal-title":"Front Oncol"},{"key":"2265_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jhep.2013.01.011","volume":"58","author":"C-W Lin","year":"2013","unstructured":"Lin C-W, Zhang H, Li M, Xiong X, Chen X, Chen X, et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol. 2013;58:993\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2013.01.011.","journal-title":"J Hepatol"},{"key":"2265_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.06.017","volume":"340","author":"S-Y Sun","year":"2013","unstructured":"Sun S-Y. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013;340:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2013.06.017.","journal-title":"Cancer Lett"},{"key":"2265_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2021.08.010","volume":"157","author":"RJ Morscher","year":"2021","unstructured":"Morscher RJ, Brard C, Berlanga P, Marshall LV, Andr\u00e9 N, Rubino J, et al. First-in-child phase I\/II study of the dual mTORC1\/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcS\u00e9-ESMART trial. Eur J Cancer. 2021;157:268\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.010.","journal-title":"Eur J Cancer"},{"key":"2265_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00011-024-01894-5","volume":"73","author":"TB Shaikh","year":"2024","unstructured":"Shaikh TB, Chandra Y, Andugulapati SB, Sistla R. Vistusertib improves pulmonary inflammation and fibrosis by modulating inflammatory\/oxidative stress mediators via suppressing the mTOR signalling. Inflamm Res. 2024;73:1223\u201337. https:\/\/doi.org\/10.1007\/s00011-024-01894-5.","journal-title":"Inflamm Res"},{"key":"2265_CR15","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1158\/1535-7163.MCT-15-0029","volume":"14","author":"BW Chen","year":"2015","unstructured":"Chen BW, Chen W, Liang H, Liu H, Liang C, Zhi X, et al. Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of Doxorubicin by suppressing MDR1 expression in HCC cells. Mol Cancer Ther. 2015;14:1805\u201315. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0029.","journal-title":"Mol Cancer Ther"},{"key":"2265_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14040370","author":"C Leyh","year":"2024","unstructured":"Leyh C, Coombes JD, Schmidt HH, Canbay A, Manka PP, Best J. MASLD-Related HCC\u2014update on pathogenesis and current treatment options. J Pers Med. 2024. https:\/\/doi.org\/10.3390\/jpm14040370. (Multidisciplinary Digital Publishing Institute (MDPI)).","journal-title":"J Pers Med"},{"key":"2265_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155182","volume":"123","author":"N Sharma","year":"2024","unstructured":"Sharma N, Sistla R, Andugulapati SB. Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt\/\u03b2-catenin pathway. Phytomedicine. 2024;123:155182. https:\/\/doi.org\/10.1016\/j.phymed.2023.155182.","journal-title":"Phytomedicine"},{"key":"2265_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70050","author":"N Sharma","year":"2025","unstructured":"Sharma N, Chandra Y, Andugulapati SB. Inhibition of MALT1 protease attenuates Hepatic Sinusoidal Obstruction Syndrome by modulating NRF2\/HO1 and NF-\u03baB pathway. Liver Int. 2025. https:\/\/doi.org\/10.1111\/liv.70050. (John Wiley and Sons Inc).","journal-title":"Liver Int"},{"key":"2265_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118308","author":"S Bhulakshmi","year":"2026","unstructured":"Bhulakshmi S, Sharma N, Yaladanda N, Lakshma Nayak V, Adepu R, Mutheneni SR, et al. Design and synthesis of Entadamide A derivatives targeting breast cancer: insights into in silico, in vitro and in vivo models. Eur J Med Chem. 2026. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118308.","journal-title":"Eur J Med Chem"},{"key":"2265_CR20","doi-asserted-by":"publisher","first-page":"G713","DOI":"10.1152\/ajpgi.00251.2017","volume":"315","author":"LL Jophlin","year":"2018","unstructured":"Jophlin LL, Koutalos Y, Chen C, Shah V, Rockey DC. Hepatic stellate cells retain retinoid-laden lipid droplets after cellular transdifferentiation into activated myofibroblasts. Am J Physiol Gastrointest Liver Physiol. 2018;315:G713\u201321. https:\/\/doi.org\/10.1152\/ajpgi.00251.2017. (American Physiological Society).","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2265_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672222","author":"X Liu","year":"2021","unstructured":"Liu X, He M, Li L, Wang X, Han S, Zhao J, et al. EMT and cancer cell stemness associated with chemotherapeutic resistance in esophageal cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.672222.","journal-title":"Front Oncol"},{"key":"2265_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/ije\/6430023","volume":"2025","author":"AM Mousa","year":"2025","unstructured":"Mousa AM, Mahmoud M, AlShuraiaan GM. Resmetirom: the first disease-specific treatment for MASH. Int J Endocrinol. 2025;2025:6430023. https:\/\/doi.org\/10.1155\/ije\/6430023.","journal-title":"Int J Endocrinol"},{"key":"2265_CR23","doi-asserted-by":"publisher","unstructured":"Wegovy approved for MASH. Nat Biotechnol [Internet]. 2025;43:1404. https:\/\/doi.org\/10.1038\/s41587-025-02828-0","DOI":"10.1038\/s41587-025-02828-0"},{"key":"2265_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-24927-3","volume":"15","author":"T Sugawara","year":"2025","unstructured":"Sugawara T, Hitaka K, Matsumoto M, Nakamura S, Kobayashi R, Kandori H, et al. Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in Western diet-fed MC4R-knockout mice. Sci Rep. 2025;15:41068. https:\/\/doi.org\/10.1038\/s41598-025-24927-3.","journal-title":"Sci Rep"},{"key":"2265_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s44355-024-00004-w","volume":"1","author":"X-D Zhou","year":"2024","unstructured":"Zhou X-D, Wong VW-S, Zheng M-H. Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive. npj Gut Liver. 2024;1:4. https:\/\/doi.org\/10.1038\/s44355-024-00004-w.","journal-title":"npj Gut Liver"},{"key":"2265_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166901","volume":"8","author":"DC Gomez-Manjarres","year":"2023","unstructured":"Gomez-Manjarres DC, Axell-House DB, Patel DC, Odackal J, Yu V, Burdick MD, et al. Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial. JCI Insight. 2023;8:e166901. https:\/\/doi.org\/10.1172\/jci.insight.166901.","journal-title":"JCI Insight"},{"key":"2265_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","volume":"71","author":"PF Mercer","year":"2016","unstructured":"Mercer PF, Woodcock HV, Eley JD, Plat\u00e9 M, Sulikowski MG, Durrenberger PF, et al. Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax. 2016;71:701\u201311. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207429. ([Internet]. BMJ Publishing Group Ltd;).","journal-title":"Thorax"},{"key":"2265_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","volume":"8","author":"P Heudel","year":"2022","unstructured":"Heudel P, Frenel J-S, Dalban C, Bazan F, Joly F, Arnaud A, et al. Safety and efficacy of the mTOR inhibitor, Vistusertib, combined with Anastrozole in patients with hormone receptor\u2212positive recurrent or metastatic endometrial cancer: the VICTORIA multicenter, open-label, phase 1\/2 randomized clinical trial. JAMA Oncol. 2022;8:1001\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1047.","journal-title":"JAMA Oncol"},{"key":"2265_CR29","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00019","author":"X Feng","year":"2024","unstructured":"Feng X, Zhang R, Yang Z, Zhang K, Xing J. Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism. J Clin Transl Hepatol. 2024. https:\/\/doi.org\/10.14218\/JCTH.2024.00019. (Xia and He Publishing Inc.;).","journal-title":"J Clin Transl Hepatol"},{"key":"2265_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-0041-1731709","volume":"42","author":"J Zhou","year":"2021","unstructured":"Zhou J, Calvisi DF, Chen XYT. Role of lipogenesis rewiring in Hepatocellular Carcinoma. Semin Liver Dis. 2021;42:77\u201386. https:\/\/doi.org\/10.1055\/s-0041-1731709.","journal-title":"Semin Liver Dis"},{"key":"2265_CR31","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI41636","volume":"122","author":"F Benhamed","year":"2012","unstructured":"Benhamed F, Denechaud P-D, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 2012;122:2176\u201394. https:\/\/doi.org\/10.1172\/JCI41636.","journal-title":"J Clin Invest"},{"key":"2265_CR32","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI89934","volume":"127","author":"D Zhang","year":"2017","unstructured":"Zhang D, Tong X, VanDommelen K, Gupta N, Stamper K, Brady GF, et al. Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. J Clin Invest. 2017;127:2855\u201367. https:\/\/doi.org\/10.1172\/JCI89934.","journal-title":"J Clin Invest"},{"key":"2265_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8:375. https:\/\/doi.org\/10.1038\/s41392-023-01608-z.","journal-title":"Signal Transduct Target Ther"},{"key":"2265_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070813","author":"J Chen","year":"2022","unstructured":"Chen J, Liu Y, Luo H, Chen G, Zheng Z, Wang T, et al. Inflammation induced by Lipopolysaccharide and Palmitic Acid increases cholesterol accumulation via enhancing Myeloid Differentiation Factor 88 expression in HepG2 cells. Pharmaceuticals Basel. 2022. https:\/\/doi.org\/10.3390\/ph15070813.","journal-title":"Pharmaceuticals Basel"},{"key":"2265_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2025.100737","volume":"80","author":"IVA Pereira","year":"2025","unstructured":"Pereira IVA, de Oliveira ABS, Zitelli PMY, Barbieri LA, Cardoso AC, Monteiro MJdeSD, et al. Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study. Clinics Sao Paulo. 2025;80:100737. https:\/\/doi.org\/10.1016\/j.clinsp.2025.100737.","journal-title":"Clinics Sao Paulo"},{"key":"2265_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117369","volume":"242","author":"LV M\u00e1rquez-Quiroga","year":"2025","unstructured":"M\u00e1rquez-Quiroga LV, Cardoso-Lezama I, Alarc\u00f3n-S\u00e1nchez BR, Gait\u00e1n-Gonz\u00e1lez P, Idelfonso-Garc\u00eda OG, Vargas-Pozada EE, et al. The progression of Metabolic Dysfunction-associated Steatotic Liver Disease toward Hepatocellular Carcinoma in an efficient rat model. Biochem Pharmacol. 2025;242:117369. https:\/\/doi.org\/10.1016\/j.bcp.2025.117369.","journal-title":"Biochem Pharmacol"},{"key":"2265_CR37","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"V Augusto","year":"2019","unstructured":"Augusto V. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med"},{"key":"2265_CR38","doi-asserted-by":"crossref","unstructured":"Liu R, Shen Y, Nan K, Mi B, Wu T, Guo J, et al. Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma: A Meta-Analysis (PRISMA). Medicine [Internet]. 2015;94. https:\/\/journals.lww.com\/md-journal\/fulltext\/2015\/08010\/association_between_expression_of_cancer_stem_cell.44.aspx","DOI":"10.1097\/MD.0000000000001306"},{"key":"2265_CR39","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1172\/JCI66024","volume":"123","author":"T Yamashita","year":"2013","unstructured":"Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013;123:1911\u20138. https:\/\/doi.org\/10.1172\/JCI66024.","journal-title":"J Clin Invest"},{"key":"2265_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102746","volume":"12","author":"H-Y Lee","year":"2020","unstructured":"Lee H-Y, Hong I-S. Targeting liver cancer stem cells: an alternative therapeutic approach for liver cancer. Cancers (Basel). 2020;12:2746. https:\/\/doi.org\/10.3390\/cancers12102746.","journal-title":"Cancers (Basel)"},{"key":"2265_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89931-9","volume":"11","author":"W Yin","year":"2021","unstructured":"Yin W, Xiang D, Wang T, Zhang Y, Pham CV, Zhou S, et al. The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep. 2021;11:10791. https:\/\/doi.org\/10.1038\/s41598-021-89931-9.","journal-title":"Sci Rep"},{"key":"2265_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07077-8","volume":"15","author":"B Son","year":"2024","unstructured":"Son B, Lee W, Kim H, Shin H, Park HH. Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research. Cell Death Dis. 2024;15:696. https:\/\/doi.org\/10.1038\/s41419-024-07077-8.","journal-title":"Cell Death Dis"},{"key":"2265_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031272","volume":"22","author":"O Kwapisz","year":"2021","unstructured":"Kwapisz O, G\u00f3rka J, Korlatowicz A, Kotlinowski J, Walig\u00f3rska A, Marona P, et al. Fatty acids and a high-fat diet induce epithelial\u2013mesenchymal transition by activating TGF\u03b2 and \u03b2-Catenin in liver cells. Int J Mol Sci. 2021;22:1272. https:\/\/doi.org\/10.3390\/ijms22031272.","journal-title":"Int J Mol Sci"},{"key":"2265_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0419-7","volume":"35","author":"GJ Yoshida","year":"2016","unstructured":"Yoshida GJ. Emerging role of epithelial-mesenchymal transition in hepatic cancer. J Exp Clin Cancer Res. 2016;35:141. https:\/\/doi.org\/10.1186\/s13046-016-0419-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"2265_CR45","unstructured":"Liao H, Huang Y, Guo B, Liang B, Liu X, Ou H, et al. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma [Internet]. Am J Cancer Res. 2015. www.ajcr.us\/"},{"key":"2265_CR46","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13668","volume":"39","author":"H-F Liao","year":"2019","unstructured":"Liao H-F, Lin Y-Z, Yu C-C, Tai T-S, Hung S-K, Yang C-C, et al. mTORC1\/2 inhibitor served as a more ideal agent against the growth of mouse lymphocytic leukemia both In Vitro and In Vivo. Anticancer Res. 2019;39:4829. https:\/\/doi.org\/10.21873\/anticanres.13668.","journal-title":"Anticancer Res"},{"key":"2265_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151069","volume":"11","author":"ES Jang","year":"2016","unstructured":"Jang ES, Jeong S-H, Kim J-W, Choi YS, Leissner P, Brechot C. Diagnostic performance of alpha-fetoprotein, protein induced by vitamin K absence, osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma. PLoS ONE. 2016;11:e0151069-. https:\/\/doi.org\/10.1371\/journal.pone.0151069.","journal-title":"PLoS ONE"},{"key":"2265_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115447","volume":"167","author":"M Arora","year":"2023","unstructured":"Arora M, Pavl\u00edkov\u00e1 Z, Ku\u010dera T, Kozl\u00edk P, \u0160opin T, Vac\u00edk T, et al. Pharmacological effects of mTORC1\/C2 inhibitor in a preclinical model of NASH progression. Biomed Pharmacother. 2023;167:115447. https:\/\/doi.org\/10.1016\/j.biopha.2023.115447.","journal-title":"Biomed Pharmacother"},{"key":"2265_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf8271","volume":"376","author":"BS Gosis","year":"2022","unstructured":"Gosis BS, Wada S, Thorsheim C, Li K, Jung S, Rhoades JH, et al. Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1. Science. 2022;376:eabf8271. https:\/\/doi.org\/10.1126\/science.abf8271.","journal-title":"Science"},{"key":"2265_CR50","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","volume":"23","author":"KG Pike","year":"2013","unstructured":"Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HME, Gomez S, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett. 2013;23:1212\u20136. https:\/\/doi.org\/10.1016\/j.bmcl.2013.01.019.","journal-title":"Bioorg Med Chem Lett"},{"key":"2265_CR51","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10637-019-00875-4","volume":"38","author":"S Lapointe","year":"2020","unstructured":"Lapointe S, Mason W, MacNeil M, Harlos C, Tsang R, Sederias J, et al. A phase I study of vistusertib (dual mTORC1\/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Invest New Drugs. 2020;38:1137\u201344. https:\/\/doi.org\/10.1007\/s10637-019-00875-4.","journal-title":"Invest New Drugs"},{"key":"2265_CR52","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","volume":"29","author":"B Basu","year":"2018","unstructured":"Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, et al. Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol. 2018;29:1918\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdy245.","journal-title":"Ann Oncol"},{"key":"2265_CR53","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41423-022-00872-3","volume":"19","author":"W Tang","year":"2022","unstructured":"Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 2022;19:834\u201347. https:\/\/doi.org\/10.1038\/s41423-022-00872-3.","journal-title":"Cell Mol Immunol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02265-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02265-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02265-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:59:36Z","timestamp":1781189976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02265-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02265-y","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"121"}}